BioNTech’s acquisition of CureVac for approximately $1.25 billion closes lingering mRNA patent disputes and enhances its mRNA cancer immunotherapy capabilities. The all-stock deal values CureVac at a 55% premium, bringing BioNTech greater manufacturing capacity and state-of-the-art research infrastructure in Tübingen, Germany. This consolidation aligns with BioNTech's push to become an integrated immunotherapy leader, with focused oncology programs including PD-L1xVEGF bispecific antibodies and mRNA-based cancer treatments. CureVac’s shift to oncology following its unsuccessful COVID-19 vaccine efforts and layoffs complements BioNTech’s expansion strategy.